Last updated: April 17, 2024
Sponsor: Taipei Medical University Shuang Ho Hospital
Overall Status: Active - Recruiting
Phase
4
Condition
Rectal Disorders
Treatment
Placebo
Micronized purified flavonoid fraction(Daflon 1000mg)
Clinical Study ID
NCT06184438
N202309013
Ages 20-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients who undergo fistulectomy or fistulotomy are included.
Exclusion
Exclusion Criteria:
- Emergency operation
- Participants who had Trans-sphincteric anal fistula, Extra-sphincteric anal fistula
- Participants accompanied by severe liver cirrhosis
- Participants accompanied by coagulation disorders
- Participants taking anticoagulant
- Participants taking corticosteroids as long-term medication.
- Participants who had colorectal cancer
- Participants taking analgesic drugs (morphine or others) as long-term medication
- Participants bed-ridden
- Participants who had history of human immunodeficiency virus (HIV) infection
- Pregnant woman
Study Design
Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 4
Study Start date:
December 13, 2023
Estimated Completion Date:
March 31, 2026
Study Description
Connect with a study center
Taipei Medical University Shuang-Ho Hospital
New Taipei City, 235
TaiwanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.